Literature DB >> 14729644

Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium.

Daniel B Martin1, David R Gifford, Michael E Wright, Andrew Keller, Eugene Yi, David R Goodlett, Reudi Aebersold, Peter S Nelson.   

Abstract

Prostate cancer is unusual among neoplasms in that it may be diagnosed at a curable stage through detection of a protein in serum, the serine protease prostate-specific antigen (PSA). PSA is secreted by both normal and neoplastic prostate epithelial cells in response to androgenic hormones and has found widespread use in cancer screening. Because PSA screening is controversial due to sensitivity and specificity issues, efforts continue to focus on the identification and characterization of additional markers that may be used for diagnostic and therapeutic purposes. In this study, we report the application of quantitative proteomic techniques that incorporate isotope coded affinity tag reagents and tandem mass spectrometry to comprehensively identify secreted and cell surface proteins from neoplastic prostate epithelium. LNCaP cells, a prostate tumor-derived cell line that secretes PSA in response to androgen exposure, were grown in a low protein-defined media under androgen-stimulated (A+) and -starved (A-) conditions. Proteomic analysis of the media identified in excess of 600 proteins, 524 of which could be quantified. Nine percent of the proteins had A+/A- ratios > 2.0, including PSA, and 2.5% had ratios < 0.5. A subset of these androgen-regulated proteins appeared to be expressed in abundance. Of these, selected mass spectrometry observations were confirmed by Western analysis. The findings suggest that androgen-mediated release of proteins may occur through the activation of proteolytic enzymes rather than exclusively through transcriptional or translational control mechanisms. On the basis of their known functional roles, several of the abundant androgen-regulated proteins may participate in the progression of neoplastic epithelial cell growth and should be considered as potential serum markers of neoplastic prostate diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729644     DOI: 10.1158/0008-5472.can-03-2062

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Investigation of neutral loss during collision-induced dissociation of peptide ions.

Authors:  Daniel B Martin; Jimmy K Eng; Alexey I Nesvizhskii; Andrew Gemmill; Ruedi Aebersold
Journal:  Anal Chem       Date:  2005-08-01       Impact factor: 6.986

2.  Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer.

Authors:  Barbara Comuzzi; Marianne D Sadar
Journal:  Cellscience       Date:  2006-07-27

Review 3.  Oxidative protein folding and the Quiescin-sulfhydryl oxidase family of flavoproteins.

Authors:  Vamsi K Kodali; Colin Thorpe
Journal:  Antioxid Redox Signal       Date:  2010-10       Impact factor: 8.401

Review 4.  Generating disulfides with the Quiescin-sulfhydryl oxidases.

Authors:  Erin J Heckler; Pumtiwitt C Rancy; Vamsi K Kodali; Colin Thorpe
Journal:  Biochim Biophys Acta       Date:  2007-10-12

5.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

6.  Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.

Authors:  Chris Planque; Vathany Kulasingam; Chris R Smith; Karen Reckamp; Lee Goodglick; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2009-09-23       Impact factor: 5.911

7.  Disulfide bond generation in mammalian blood serum: detection and purification of quiescin-sulfhydryl oxidase.

Authors:  Benjamin A Israel; Lingxi Jiang; Shawn A Gannon; Colin Thorpe
Journal:  Free Radic Biol Med       Date:  2014-01-25       Impact factor: 7.376

8.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

9.  Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.

Authors:  Adaikkalam Vellaichamy; Arun Sreekumar; John R Strahler; Theckelnaycke Rajendiran; Jindan Yu; Sooryanarayana Varambally; Yong Li; Gilbert S Omenn; Arul M Chinnaiyan; Alexey I Nesvizhskii
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

10.  Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis.

Authors:  C Puri; M V Chibalina; S D Arden; A J Kruppa; J Kendrick-Jones; F Buss
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.